Inhibrxinc Stock Performance
| INBX Stock | USD 34.45 0.16 0.46% |
InhibrxInc has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.62, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, InhibrxInc's returns are expected to increase less than the market. However, during the bear market, the loss of holding InhibrxInc is expected to be smaller as well. InhibrxInc right now retains a risk of 1.75%. Please check out InhibrxInc maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if InhibrxInc will be following its current trending patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in InhibrxInc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong fundamental drivers, InhibrxInc is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.46) | Five Day Return (1.03) | Year To Date Return (9.44) | Ten Year Return 66.99 | All Time Return 66.99 |
1 | Do Analysts Agree Friday on Inhibrx Inc Stocks Target Price - InvestorsObserver | 02/09/2024 |
2 | Inhibrx Reaches New 52-Week High at .79 | 02/27/2024 |
3 | Inhibrx, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/28/2024 |
4 | Disposition of 10417 shares by Deck Kelly of InhibrxInc at 34.16 subject to Rule 16b-3 | 03/05/2024 |
5 | Disposition of 400 shares by Brendan Eckelman of InhibrxInc at 24.7075 subject to Rule 16b-3 | 03/08/2024 |
6 | Disposition of 6877 shares by Brendan Eckelman of InhibrxInc at 33.63 subject to Rule 16b-3 | 03/11/2024 |
7 | Disposition of 19898 shares by Brendan Eckelman of InhibrxInc at 33.63 subject to Rule 16b-3 | 03/12/2024 |
8 | Disposition of 32431 shares by Deck Kelly of InhibrxInc at 11.25 subject to Rule 16b-3 | 03/13/2024 |
9 | Disposition of 16777 shares by Deck Kelly of InhibrxInc at 10.52 subject to Rule 16b-3 | 03/20/2024 |
10 | Disposition of 3113 shares by Deck Kelly of InhibrxInc at 10.52 subject to Rule 16b-3 | 03/21/2024 |
11 | Disposition of 110 shares by Deck Kelly of InhibrxInc at 10.52 subject to Rule 16b-3 | 03/22/2024 |
12 | Disposition of 5954 shares by Brendan Eckelman of InhibrxInc at 28.9713 subject to Rule 16b-3 | 03/25/2024 |
13 | Disposition of 416 shares by Deck Kelly of InhibrxInc at 34.16 subject to Rule 16b-3 | 03/26/2024 |
14 | As more rare disease therapies launch, their prices are rising | 04/16/2024 |
| Begin Period Cash Flow | 273.9 M |
InhibrxInc |
InhibrxInc Relative Risk vs. Return Landscape
If you would invest 3,333 in InhibrxInc on January 20, 2024 and sell it today you would earn a total of 112.00 from holding InhibrxInc or generate 3.36% return on investment over 90 days. InhibrxInc is currently generating 0.0672% in daily expected returns and assumes 1.7452% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than InhibrxInc, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
InhibrxInc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InhibrxInc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InhibrxInc, and traders can use it to determine the average amount a InhibrxInc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0385
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | INBX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.75 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average InhibrxInc is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InhibrxInc by adding it to a well-diversified portfolio.
InhibrxInc Fundamentals Growth
InhibrxInc Stock prices reflect investors' perceptions of the future prospects and financial health of InhibrxInc, and InhibrxInc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InhibrxInc Stock performance.
| Return On Equity | -4.75 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (54.03) % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 47.39 M | ||||
| Price To Book | 38.11 X | ||||
| Price To Sales | 920.99 X | ||||
| Revenue | 1.8 M | ||||
| Gross Profit | (107.99 M) | ||||
| EBITDA | (218.03 M) | ||||
| Net Income | (241.36 M) | ||||
| Cash And Equivalents | 176.38 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 210.14 M | ||||
| Debt To Equity | 4.22 % | ||||
| Current Ratio | 7.51 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (193.31 M) | ||||
| Earnings Per Share | (5.12) X | ||||
| Market Capitalization | 1.64 B | ||||
| Total Asset | 307.89 M | ||||
| Retained Earnings | (613.73 M) | ||||
| Working Capital | 239.05 M | ||||
About InhibrxInc Performance
To evaluate InhibrxInc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when InhibrxInc generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare InhibrxInc Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand InhibrxInc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents InhibrxInc's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (37.90) | (39.80) | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (5.55) | (5.27) |
Things to note about InhibrxInc performance evaluation
Checking the ongoing alerts about InhibrxInc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InhibrxInc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InhibrxInc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| InhibrxInc currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| InhibrxInc has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: As more rare disease therapies launch, their prices are rising |
- Analyzing InhibrxInc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InhibrxInc's stock is overvalued or undervalued compared to its peers.
- Examining InhibrxInc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InhibrxInc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InhibrxInc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InhibrxInc's stock. These opinions can provide insight into InhibrxInc's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InhibrxInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy InhibrxInc Stock please use our How to Invest in InhibrxInc guide.Note that the InhibrxInc information on this page should be used as a complementary analysis to other InhibrxInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for InhibrxInc Stock analysis
When running InhibrxInc's price analysis, check to measure InhibrxInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InhibrxInc is operating at the current time. Most of InhibrxInc's value examination focuses on studying past and present price action to predict the probability of InhibrxInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InhibrxInc's price. Additionally, you may evaluate how the addition of InhibrxInc to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is InhibrxInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InhibrxInc. If investors know InhibrxInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InhibrxInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.12) | Revenue Per Share 0.038 | Quarterly Revenue Growth 4.964 | Return On Assets (0.46) | Return On Equity (4.75) |
The market value of InhibrxInc is measured differently than its book value, which is the value of InhibrxInc that is recorded on the company's balance sheet. Investors also form their own opinion of InhibrxInc's value that differs from its market value or its book value, called intrinsic value, which is InhibrxInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InhibrxInc's market value can be influenced by many factors that don't directly affect InhibrxInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InhibrxInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if InhibrxInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InhibrxInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.